ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Monday, November 18, 2024

10:30AM-12:30PM: Abstract Number: 2183

Accuracy of AI Tools for Diagnosis of Connective Tissue Disease

Pediatric Rheumatology – Clinical Poster III

10:30AM-12:30PM: Abstract Number: 1975

Accurate Detection of Arthritis Using Hand-held Thermal Imaging and Machine Learning

Imaging of Rheumatic Diseases Poster II

10:30AM-12:30PM: Abstract Number: 2362

Achievement of Remission Defined by Absence of Objective Signs of Inflammation versus ASDAS ID in Patients with Active Axial Spondyloarthritis Treated with Bimekizumab: 52-Week Results from Two Phase 3 Studies

SpA Including PsA – Treatment Poster III

10:30AM-12:30PM: Abstract Number: 2449

Acid Reflux Triggers Type I Interferon and Persistent Epithelial-mesenchymal Transition in Esophageal Epithelial Cells. a Novel Microenvironment Contribution to the Pathogenesis of Systemic Sclerosis

Systemic Sclerosis & Related Disorders – Clinical Poster III

10:30AM-12:30PM: Abstract Number: 1817

Activated Macrophages Mediate Loss of Dermal White Adipose Tissue in Fibrotic Skin

Systemic Sclerosis & Related Disorders – Basic Science Poster II

10:30AM-12:30PM: Abstract Number: 2300

Activation of Tissue-Resident T Cells in Sjögren’s Disease with Human Salivary Organoids

Sjögren's Syndrome – Basic & Clinical Science Poster II

10:30AM-12:30PM: Abstract Number: 2269

Adalimumab Dose Reduction Using Therapeutic Drug Monitoring to Manage Low Disease Activity in Rheumatoid Arthritis: A Single-Blind, Non-Inferiority, Randomized Clinical Trial

RA – Treatment Poster III

10:30AM-12:30PM: Abstract Number: 2216

Additive Impact of Rheumatoid Arthritis and HBcAb+ on All-cause and Cardiovascular Mortality

RA – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 2409

Adherence to EULAR Recommendations and Sub Optimal Management of Systemic Lupus Erythematosus in a Network of Community-Based Rheumatology Practices in the United States

SLE – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 1920

Admixture Mapping and Gene-Based Analysis Identifies Rare Variants in Genes in the IL-13 and TGFβ Signaling Pathways in African Americans with Systemic Sclerosis

Healthcare Disparities in Rheumatology Poster III

10:30AM-12:30PM: Abstract Number: 1967

Advanced Imaging in the Evaluation of Lupus Arthritis: A Systematic Literature Review and Meta-Analysis

Imaging of Rheumatic Diseases Poster II

10:30AM-12:30PM: Abstract Number: 2224

Age of Onset of Rheumatoid Arthritis and Radiographic Changes

RA – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 2454

Age-Adjusted Mortality Rate Trends in Systemic Sclerosis in the United States from 1999 to 2020

Systemic Sclerosis & Related Disorders – Clinical Poster III

10:30AM-12:30PM: Abstract Number: 2239

Age, Seropositivity and Inflammation Determine Risk versus Benefit of Endogenous Estrogens on Coronary Atherosclerosis in Rheumatoid Arthritis

RA – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 2293

Altered Expression of the MicroRNA Biogenesis Machinery Components Correlates with Inflammatory Parameters in Salivary Glands of Patient with Sjögren’s Disease

Sjögren's Syndrome – Basic & Clinical Science Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].